168 related articles for article (PubMed ID: 18378563)
1. Differential genotype dependent inhibition of CYP2C9 in humans.
Kumar V; Brundage RC; Oetting WS; Leppik IE; Tracy TS
Drug Metab Dispos; 2008 Jul; 36(7):1242-8. PubMed ID: 18378563
[TBL] [Abstract][Full Text] [Related]
2. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.
Lee CR; Pieper JA; Frye RF; Hinderliter AL; Blaisdell JA; Goldstein JA
Eur J Clin Pharmacol; 2003 Apr; 58(12):791-4. PubMed ID: 12698304
[TBL] [Abstract][Full Text] [Related]
3. Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers.
Hanley MJ; Masse G; Harmatz JS; Cancalon PF; Dolnikowski GG; Court MH; Greenblatt DJ
Br J Clin Pharmacol; 2013 Apr; 75(4):1041-52. PubMed ID: 22943633
[TBL] [Abstract][Full Text] [Related]
4. Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: divergence from in vitro results.
Hanley MJ; Masse G; Harmatz JS; Court MH; Greenblatt DJ
Clin Pharmacol Ther; 2012 Nov; 92(5):651-7. PubMed ID: 23047652
[TBL] [Abstract][Full Text] [Related]
5. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies.
Greenblatt DJ; von Moltke LL; Perloff ES; Luo Y; Harmatz JS; Zinny MA
Clin Pharmacol Ther; 2006 Jan; 79(1):125-33. PubMed ID: 16413247
[TBL] [Abstract][Full Text] [Related]
6. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
[TBL] [Abstract][Full Text] [Related]
7. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.
Lee CR; Pieper JA; Frye RF; Hinderliter AL; Blaisdell JA; Goldstein JA
J Clin Pharmacol; 2003 Jan; 43(1):84-91. PubMed ID: 12520632
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant.
Hummel MA; Locuson CW; Gannett PM; Rock DA; Mosher CM; Rettie AE; Tracy TS
Mol Pharmacol; 2005 Sep; 68(3):644-51. PubMed ID: 15955872
[TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects.
Lee YJ; Byeon JY; Kim YH; Kim SH; Choi CI; Bae JW; Sohn UD; Jang CG; Lee J; Lee SY
Arch Pharm Res; 2015 Jun; 38(6):1232-7. PubMed ID: 25712887
[TBL] [Abstract][Full Text] [Related]
10. Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot.
Daali Y; Samer C; Déglon J; Thomas A; Chabert J; Rebsamen M; Staub C; Dayer P; Desmeules J
Clin Pharmacol Ther; 2012 Mar; 91(3):489-96. PubMed ID: 22237256
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity.
Zgheib NK; Frye RF; Tracy TS; Romkes M; Branch RA
Br J Clin Pharmacol; 2007 Apr; 63(4):477-87. PubMed ID: 17054666
[TBL] [Abstract][Full Text] [Related]
12. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
[TBL] [Abstract][Full Text] [Related]
13. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone.
Hutzler JM; Frye RF; Korzekwa KR; Branch RA; Huang SM; Tracy TS
Eur J Pharm Sci; 2001 Aug; 14(1):47-52. PubMed ID: 11457649
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.
Kumar V; Wahlstrom JL; Rock DA; Warren CJ; Gorman LA; Tracy TS
Drug Metab Dispos; 2006 Dec; 34(12):1966-75. PubMed ID: 16963489
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
Kantola T; Backman JT; Niemi M; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 2000 Jun; 56(3):225-9. PubMed ID: 10952477
[TBL] [Abstract][Full Text] [Related]
16. CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug.
Vogl S; Lutz RW; Schönfelder G; Lutz WK
PLoS One; 2015; 10(3):e0120403. PubMed ID: 25775139
[TBL] [Abstract][Full Text] [Related]
17. Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator.
Flora DR; Tracy TS
Drug Metab Dispos; 2012 Apr; 40(4):836-42. PubMed ID: 22205778
[TBL] [Abstract][Full Text] [Related]
18. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.
Bavisotto LM; Ellis DJ; Milner PG; Combs DL; Irwin I; Canafax DM
J Clin Pharmacol; 2011 Apr; 51(4):561-74. PubMed ID: 20622200
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
[TBL] [Abstract][Full Text] [Related]
20. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
Kaukonen KM; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Feb; 53(6):445-9. PubMed ID: 9551703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
